Monday, September 16, 2024
Program subject to change.
8:30 am - 9:30 am | Plenary Lecture 1
Endogenous Biomarker-informed Approaches for Evaluation of Transporter-mediated Drug-drug and Drug-disease Interactions
Aleksandra Galetin, University of Manchester, Manchester, United Kingdom
9:30 am - 10:00 am | Refreshment Break with Posters and Exhibitors
10:00 am - 12:00 pm | Concurrent Symposia 1 and 2
Symposium 1: DDI - From Research to Regulatory to Clinical
Co-Chairs: Akihiro Ishiguro, PMDA, Tokyo, Japan and Xinning Yang, FDA, Ellicott City, Maryland, USA
Review of Finalized ICH M12 Guideline on Drug Interaction Studies
Akihiro Ishiguro, PMDA, Toyko, Japan
Preclinical DDI Risk Assessment in Drug Discovery and Development
Niresh Hariparsad, AstraZeneca, Waltham, Massachusetts, USA
Complicated Drug-drug Interactions: Study Design and Clinical Interpretation
Manoli Vourvahis, Pfizer, New York City, New York, USA
Utilizing PBPK Modeling and In Vitro Data for Predicting Complex DDIs of OATP1B and CYP Substrates Caused by Various Perpetrators
Yuichi Sugiyama, Josai International University, Tokyo, Japan
Utility of Mechanistic Static Models for Predicting CYP- and Transporter-mediated DDI
Sheila Peters, Boehringer-Ingelheim, Mainz, Germany
Symposium 2: Beyond Small Molecule Modalities
Co-Chairs: Kenta Haraya, Chugai Pharmaceutical, Singapore and Anshul Gupta, Generation Bio, Cambridge, Massachusetts, USA
Assessment of ADME and DDI for LNP-mRNA Therapeutics
Lei Ci, Moderna Therapeutics, Cambridge, Massachusetts, USA
Targeted Protein Degraders (TPD): PK/PD Translation from Preclinical to Clinical
Dapeng Chen, Kymera Therapeutics, Watertown, Massachusetts, USA
Improving ADME Properties of Therapeutic Antibodies by Novel Engineering Technologies
Kenta Haraya, Chugai Pharmaceutical, Yokohama, Japan
Cell Therapies in Oncology and Beyond
Ganesh Mugundu, Takeda, Lexington, Massachusetts, USA
12:00 pm - 3:00 pm | Lunch, Exhibits, and Poster Presentations
12:00 pm - 1:00 pm: Lunch, Exhibit Hall Hours, and Poster Viewing
1:00 pm - 2:00 pm: A1- A6 Poster Award Finalist Presentations
2:00 pm - 3:00 pm: A7 - A12 Poster Award Finalist Presentations
3:00 pm - 5:00 pm | Concurrent Symposia 3 and 4
Symposium 3: Emerging Technologies at the Interface of Mechanistic PK and AI
Co-Chairs: Fumiyoshi Yamashita, Kyoto University, Kyoto, Japan and Fabio Broccatelli, Bristol Myers Squibb, San Diego, California, USA
AI-based Feature Generation for Molecular Design
Tadahaya Mizuno, University of Tokyo, Tokyo, Japan
Mechanistic Multiple Parameter Optimization in Drug Discovery
Fabio Broccatelli, BMS, San Diego, California, USA
Integration of Pharmacokinetic Modeling with AI Technology
Yanran Wang, Genentech, South San Francisco, California, USA
Computer Aided MetID for Small Molecules and Peptide Drugs
Ismael Zamora, Lead Molecular Design SL, Sant Cugat del Vallés, Spain
Symposium 4: Recent Advances to Study Drug Transporters
Co-Chairs: Kazuya Maeda, Kitasato University, Tokyo, Japan and Hong Shen, Bristol Myers Squibb, Princeton, New Jersey, USA
Membrane Transporters in Drug Development and as Determinants of Precision Medicine; An Update from the International Transporter Consortium
Kim Brouwer, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA
Discovery, Validation, and Application of Transporter Endogenous Biomarkers: A Work of Translation
Hong Shen, Bristol Myers Squibb, Belle Mead, New Jersey, USA
Food-derived Neurotrophic Amino Acid Ergothioneine and its Transporter SLC22A4: From Bench to Healthy Food
Yukio Kato, Kanazawa University, Kanazawa, Japan
Role of Intracellular SLC46A3 in the Cytosolic Exposure and Pharmacological Effect of the Payload of Trastuzumab Emtansine (ADC)
Katsuhisa Inoue, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan